Literature DB >> 20720591

Pharmacotherapy: ACCORD Blood Pressure and ACCORD Lipid: how low can we go?

Mariela Glandt, Itamar Raz.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20720591     DOI： 10.1038/nrendo.2010.128

Source DB:  PubMed          Journal:  Nat Rev Endocrinol        ISSN： 1759-5029            Impact factor:   43.330


× No keyword cloud information.
  9 in total

1.  Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Implications for treatment.

Authors:  V Manninen; L Tenkanen; P Koskinen; J K Huttunen; M Mänttäri; O P Heinonen; M H Frick
Journal:  Circulation       Date:  1992-01       Impact factor: 29.690

2.  Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).

Authors: 
Journal:  JAMA       Date:  2002-12-18       Impact factor: 56.272

3.  Effect of valsartan on the incidence of diabetes and cardiovascular events.

Authors:  John J McMurray; Rury R Holman; Steven M Haffner; M Angelyn Bethel; Björn Holzhauer; Tsushung A Hua; Yuri Belenkov; Mitradev Boolell; John B Buse; Brendan M Buckley; Antonio R Chacra; Fu-Tien Chiang; Bernard Charbonnel; Chun-Chung Chow; Melanie J Davies; Prakash Deedwania; Peter Diem; Daniel Einhorn; Vivian Fonseca; Gregory R Fulcher; Zbigniew Gaciong; Sonia Gaztambide; Thomas Giles; Edward Horton; Hasan Ilkova; Trond Jenssen; Steven E Kahn; Henry Krum; Markku Laakso; Lawrence A Leiter; Naomi S Levitt; Viacheslav Mareev; Felipe Martinez; Chantal Masson; Theodore Mazzone; Eduardo Meaney; Richard Nesto; Changyu Pan; Rudolf Prager; Sotirios A Raptis; Guy E H M Rutten; Herbert Sandstroem; Frank Schaper; Andre Scheen; Ole Schmitz; Isaac Sinay; Vladimir Soska; Steen Stender; Gyula Tamás; Gianni Tognoni; Jaako Tuomilehto; Alberto S Villamil; Juraj Vozár; Robert M Califf
Journal:  N Engl J Med       Date:  2010-03-14       Impact factor: 91.245

4.  Effects of intensive blood-pressure control in type 2 diabetes mellitus.

Authors:  William C Cushman; Gregory W Evans; Robert P Byington; David C Goff; Richard H Grimm; Jeffrey A Cutler; Denise G Simons-Morton; Jan N Basile; Marshall A Corson; Jeffrey L Probstfield; Lois Katz; Kevin A Peterson; William T Friedewald; John B Buse; J Thomas Bigger; Hertzel C Gerstein; Faramarz Ismail-Beigi
Journal:  N Engl J Med       Date:  2010-03-14       Impact factor: 91.245

5.  Effects of combination lipid therapy in type 2 diabetes mellitus.

Authors:  Henry N Ginsberg; Marshall B Elam; Laura C Lovato; John R Crouse; Lawrence A Leiter; Peter Linz; William T Friedewald; John B Buse; Hertzel C Gerstein; Jeffrey Probstfield; Richard H Grimm; Faramarz Ismail-Beigi; J Thomas Bigger; David C Goff; William C Cushman; Denise G Simons-Morton; Robert P Byington
Journal:  N Engl J Med       Date:  2010-03-14       Impact factor: 91.245

6.  Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease.

Authors: 
Journal:  Circulation       Date:  2000-07-04       Impact factor: 29.690

7.  Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial.

Authors:  A Keech; R J Simes; P Barter; J Best; R Scott; M R Taskinen; P Forder; A Pillai; T Davis; P Glasziou; P Drury; Y A Kesäniemi; D Sullivan; D Hunt; P Colman; M d'Emden; M Whiting; C Ehnholm; M Laakso
Journal:  Lancet       Date:  2005-11-26       Impact factor: 79.321

8.  Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial.

Authors:  Anushka Patel; S MacMahon; J Chalmers; B Neal; M Woodward; L Billot; S Harrap; N Poulter; M Marre; M Cooper; P Glasziou; D E Grobbee; P Hamet; S Heller; L S Liu; G Mancia; C E Mogensen; C Y Pan; A Rodgers; B Williams
Journal:  Lancet       Date:  2007-09-08       Impact factor: 79.321

9.  Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group.

Authors:  L Hansson; A Zanchetti; S G Carruthers; B Dahlöf; D Elmfeldt; S Julius; J Ménard; K H Rahn; H Wedel; S Westerling
Journal:  Lancet       Date:  1998-06-13       Impact factor: 79.321
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.